Concepts (75)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 5 | 2020 | 14 | 1.400 |
Why?
|
| Gynecology | 2 | 2018 | 7 | 0.620 |
Why?
|
| Medical Oncology | 2 | 2018 | 35 | 0.600 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 33 | 0.580 |
Why?
|
| Registries | 1 | 2018 | 170 | 0.550 |
Why?
|
| Ovarian Neoplasms | 4 | 2019 | 62 | 0.430 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 8 | 0.370 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2018 | 32 | 0.360 |
Why?
|
| Endometrial Neoplasms | 2 | 2022 | 12 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 75 | 0.290 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 450 | 0.260 |
Why?
|
| Female | 13 | 2022 | 14273 | 0.210 |
Why?
|
| Urogenital Abnormalities | 1 | 2021 | 7 | 0.190 |
Why?
|
| Infertility, Female | 1 | 2021 | 11 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2021 | 22 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 222 | 0.180 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 7 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 6 | 0.160 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2018 | 1 | 0.160 |
Why?
|
| Hydrazines | 1 | 2018 | 7 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 9 | 0.160 |
Why?
|
| Dextrocardia | 1 | 2018 | 2 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 7 | 0.160 |
Why?
|
| Paclitaxel | 1 | 2018 | 41 | 0.160 |
Why?
|
| Piperazines | 1 | 2019 | 75 | 0.150 |
Why?
|
| Humans | 13 | 2022 | 25692 | 0.150 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 12 | 0.150 |
Why?
|
| Electrocardiography | 1 | 2018 | 101 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2018 | 59 | 0.140 |
Why?
|
| Certification | 1 | 2018 | 47 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 169 | 0.140 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 4 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2018 | 132 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 284 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 154 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 184 | 0.120 |
Why?
|
| Cervix Mucus | 1 | 2013 | 4 | 0.110 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2013 | 2 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 53 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 23 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2013 | 56 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2013 | 127 | 0.100 |
Why?
|
| United States | 1 | 2018 | 1943 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2022 | 341 | 0.100 |
Why?
|
| Middle Aged | 5 | 2019 | 8403 | 0.100 |
Why?
|
| Survival Rate | 1 | 2011 | 308 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2020 | 72 | 0.080 |
Why?
|
| Tomography, X-Ray | 1 | 2009 | 2 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 84 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 1077 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 107 | 0.070 |
Why?
|
| Adult | 3 | 2018 | 7336 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 4459 | 0.070 |
Why?
|
| Aged | 3 | 2018 | 8501 | 0.060 |
Why?
|
| Quality of Life | 2 | 2020 | 600 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 1855 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2022 | 19 | 0.050 |
Why?
|
| Sirolimus | 1 | 2022 | 18 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2011 | 3231 | 0.050 |
Why?
|
| Strategic Planning | 1 | 2021 | 7 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3220 | 0.050 |
Why?
|
| Uterus | 1 | 2021 | 14 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2021 | 22 | 0.050 |
Why?
|
| Mutation | 1 | 2022 | 325 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 21 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 29 | 0.040 |
Why?
|
| Heart | 1 | 2018 | 57 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2016 | 51 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 66 | 0.030 |
Why?
|
| Metaplasia | 1 | 2013 | 3 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 40 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 292 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 443 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 392 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 351 | 0.020 |
Why?
|